

# Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers

Kristin M. Aakre <sup>a,b,\*</sup> Amy K. Saenger,<sup>c,d</sup> Rick Body <sup>e,f,g</sup> Paul Collinson <sup>h,i</sup> Ola Hammarsten,<sup>j</sup> Allan S. Jaffe,<sup>k</sup> Pete Kavsak,<sup>l</sup> Torbjørn Omland,<sup>m,n</sup> Jordi Ordonez-Lianos,<sup>o,p</sup> and Fred S. Apple<sup>c,d</sup>

The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides evidence-based educational documents to facilitate uniform interpretation and utilization of cardiac biomarkers in clinical laboratories and practice. The committee's goals are to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay in clinical practice. Measurement of high-sensitivity cardiac troponin (hs-cTn) assays is a cornerstone in the clinical evaluation of patients with symptoms and/or signs of acute cardiac ischemia. To define myocardial infarction, the Universal Definition of Myocardial Infarction requires patients who manifest with features suggestive of acute myocardial ischemia to have at least one cTn concentration above the sex-specific 99th percentile upper reference limit (URL) for hs-cTn assays and a dynamic pattern of cTn concentrations to fulfill the diagnostic criteria for MI. This special report provides an overview of how hs-cTn 99th percentile URLs should be established, including recommendations about prescreening and the number of individuals required in the reference cohort, how statistical analysis should be conducted, optimal preanalytical and analytical protocols, and analytical/biological interferences or

confounds that can affect accurate determination of the 99th percentile URLs. This document also provides guidance and solutions to many of the issues posed.

## Introduction

Cardiac troponin (cTn) measurements play a fundamental role in defining myocardial infarction (MI) per the Universal Definition of Myocardial Infarction (UDMI) guidelines (1). High-sensitivity cTn (hs-cTn) assays are recommended. hs-cTn testing permits the early and rapid exclusion of MI in the emergency department (ED) in a substantial number of patients in addition to identifying those with a very high probability of MI (2–4). hs-cTn testing also provides classification of those at short- and long-term risk for major adverse cardiovascular events and mortality even in the absence of MI. The 99th percentile upper reference limit (URL) has been endorsed as the recommended hs-cTn threshold in the UDMI and the laboratory medicine community for over 20 years (1, 5–7). Clinical diagnostic criteria include a rise and/or fall in hs-cTn concentrations with at least one value above the 99th percentile

<sup>a</sup>Department of Medical Biochemistry and Pharmacology and Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; <sup>b</sup>Department of Clinical Science, University of Bergen, Bergen, Norway; <sup>c</sup>Department of Laboratory Medicine and Pathology, Hennepin Healthcare/HCMC, Minneapolis, MN, USA; <sup>d</sup>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA; <sup>e</sup>Emergency Department, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; <sup>f</sup>Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK; <sup>g</sup>Healthcare Sciences Department, Manchester Metropolitan University, Manchester, UK; <sup>h</sup>Department of Clinical Blood Sciences and Cardiology, St George's University Hospitals NHS Foundation Trust, London, UK; <sup>i</sup>Departments of Clinical Blood Sciences and Cardiology, St George's University of London, London, UK; <sup>j</sup>Department of Clinical Chemistry and

Transfusion Medicine, University of Gothenburg, Gothenburg, Sweden; <sup>k</sup>Departments of Laboratory Medicine and Pathology and Cardiology, Mayo Clinic, Rochester, MN, USA; <sup>l</sup>Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; <sup>m</sup>Department of Cardiology, Akershus University Hospital, Lørenskog, Norway; <sup>n</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway; <sup>o</sup>Servicio de Bioquímica Clínica, Institut d'Investigacions Biomèdiques Sant Pau, Barcelona, Spain; <sup>p</sup>Departamento de Bioquímica y Biología Molecular, Universidad Autònoma de Barcelona, Barcelona, Spain.

\*Address correspondence to this author at: Department of Medical Biochemistry and Pharmacology, Postbox 1400, Haukeland University Hospital, 5021 Bergen, Norway. Fax +47 55975976; E-mail kristin.moberg.aakre@helse-bergen.no.  
Received March 31, 2022; accepted April 27, 2022.  
<https://doi.org/10.1093/clinchem/hvac092>

sex-specific URLS, all taken in conjunction with clinical findings thought to be indicative of acute ischemia (1).

The 99th percentile is derived from cTn measurements in an apparently healthy cohort and is dependent on participant selection, statistical analyses, and analytical and biological variability. These metrics are not standardized between studies; therefore, different 99th percentiles may be recommended for the same hs-cTn assay (8–10), which can potentially lead to nonconformity of how acute MI is diagnosed. This issue is accentuated by the fact that many centers do not even use the 99th percentile URL. This is problematic for the individual patient who may receive a different diagnosis depending on which URL the local hospital has implemented. It is also challenging from an epidemiological standpoint, making comparisons between hospitals in the same region difficult and potentially masking differences in treatment, follow-up, and survival. To increase harmonization of an MI diagnosis, a common protocol for deriving 99th percentile URLS should be applied in similar ethnic/racial populations. This may be accomplished in several ways, but one feasible option is the use of large high-quality studies deriving 99th URLS that are applicable for different population regions. These should then be documented and communicated within the manufacturers' package inserts and thereafter implemented by the local laboratories in the relevant region. This special report provides an overview of how 99th percentile URLS should be derived and recommendations that may be useful for manufacturers, clinical laboratories, and research studies aimed at harmonizing the diagnosis of MI. We include some changes, modifications, and clarifications in comparison to previous recommendations that are intended to increase the robustness of future 99th percentile URL determinations, including the following areas: (a) preinclusion screening procedures needed to document and ensure all subjects in the reference cohort are healthy; (b) an increase in the number of male and female subjects, to allow for improved accuracy when calculating the sex-specific 95% CI for the 99th percentile; (c) investigation of biological interferences in specimens that demonstrate unexpected hs-cTn concentrations, based on clinical assessment or statistical outlier analyses; (d) standardization of preanalytical factors and elimination of analytical interferences; and (e) utilization of several reagent and calibrator lots to reduce influences in lot shifts when determining the hs-cTn 99th percentile.

## Cardiac Troponin 99th Percentile URLS Applied in the Universal Definition of Myocardial Infarction

Clinical laboratory reference intervals are fundamental tools utilized by the medical community and patients


to interpret laboratory test results and distinguish between health conditions defined as normal or abnormal. Categorization as abnormal may imply disease but could also be an unintentional finding without any clinical implication, since a certain percentage of healthy individuals by definition will be measured outside the URL depending on the percentile used to differentiate between the 2 conditions. hs-cTn measurements differ from many other laboratory assays in that the assay-specific 99th percentile, not the 97th percentile, serves as the URL and is used as a diagnostic cutoff for myocardial injury of any etiology and, in the proper clinical setting, to support the diagnosis of acute MI.

### RECOMMENDATION 1: HIGH-SENSITIVITY CARDIAC TROPONIN CONCENTRATIONS ABOVE THE SEX-SPECIFIC 99TH PERCENTILE URL SHOULD BE USED AS THE DIAGNOSTIC THRESHOLD FOR MYOCARDIAL INJURY AND MI, CONSISTENT WITH THE UNIVERSAL DEFINITION OF MYOCARDIAL INFARCTION

The Fourth Universal Definition of Myocardial Infarction (1) defines cTn concentrations above the sex-specific 99th percentile of the assay as “myocardial injury” (Fig. 1). Acute myocardial injury requires at least one cTn concentration above the 99th percentile in conjunction with dynamic changes (1). Acute myocardial injury can be of ischemic or nonischemic origin and occurs due to multiple pathological or even physiological causes (1). An acute MI is diagnosed when acute myocardial injury and myocardial ischemia are simultaneously present, based on clinical, electrocardiogram, or imaging findings and documentation. Several types of MI can be defined based on the pathophysiology. Type 1 MI is due to plaque disruption with coronary atherothrombosis while type 2 occurs in the absence of acute plaque disruption in a clinical setting with oxygen demand and supply imbalance (1). The latter may be caused by multiple etiologies (e.g., coronary spasms, embolism or artery dissection, sustained brady or tachyarrhythmia, severe anemia, hypotension, respiratory failure) (1).

Acute myocardial injury due to nonischemic causes may occur from noncoronary heart disease (e.g., heart failure, myocarditis, Takotsubo syndrome, cardiac procedures, or contusion) or systemic causes such as sepsis, severe illness, chronic kidney disease, toxic agents, stroke, pulmonary embolism, or even intense physical exercise. hs-cTn concentrations increase rapidly during acute myocardial injury, and accordingly low baseline and 1- or 2-h delta values are used for early rule out and prediction of low risk of myocardial injury in patients presenting to the ED with symptoms suggestive of non-ST-elevation MI (NSTEMI) (Fig. 1).

The 0/1 h algorithm as well as the 0/2 h algorithm, both recommended by the European Society of



Cardiology, also include criteria to assist in the “rule in” of patients at high risk of MI based either upon a single high threshold (higher than the 99th percentile) or a delta observed on serial sampling at 1 h. It is important to note that these rule-in criteria do not usurp the use of the 99th percentile URL as the standard cutoff for diagnosing myocardial injury and MI. Rather, the criteria specified in 0/1 h and 0/2 h algorithms can be used as a surrogate to rapidly identify patients with high probability of MI. However, the positive predictive value of such criteria is generally <80% (11–14), and in cohorts with low prevalence of NSTEMI, it may be substantially lower. Therefore, the diagnosis of MI should still be confirmed based on the criteria specified in the UDMI.

Chronic myocardial injury is characterized by increased serial hs-cTn concentrations that do not change acutely ( $\leq \pm 20\%$  variation as suggested by UDMI [1]), frequently caused by structural heart disease such as hypertension or left ventricular dysfunction (15), long-term cardiac exposure to multiple metabolic risk factors (16), or toxic substances including drugs (17). Chronic increases in hs-cTn often signal a poor long-term prognosis, including an increased risk for cardiovascular diseases and mortality. Large observational studies have demonstrated an association between long-term prognosis and hs-cTn concentrations even lower than the 99th percentile, and it appears that there is a continuous relationship from the limit of detection of an assay, including all normal values up to the 99th percentile URL (18). Accordingly, even hs-cTn concentrations between the limit of detection and the 99th percentile URL are associated

with increased risk in patients who presented to the ED but never demonstrate a hs-cTn > 99th percentile during their hospital presentation (19) (Fig. 1) and in those for whom hs-cTn is obtained for risk assessment.

The majority of analyte reference intervals are derived statistically using the central 95th percentile distribution of results from a presumably healthy cohort (20). Although the 97.5th percentile has been proposed by some as the appropriate diagnostic cutoff for MI using hs-cTn assays, the 99th percentile remains the reference standard for diagnosis of myocardial injury and MI and has been embedded within UDMI, IFCC, and AACC guidelines (1, 5–7) since 2000. The 99th percentile was initially recommended to avoid large imprecision associated with the first generations of cTn assays, which would influence clinical interpretation (21). Use of the 97.5th percentile would have resulted in a significantly higher misclassification rate of healthy individuals (2.5% vs 1.0%). Previously, diagnosis of MI using creatine kinase MB utilized twice the URL. Contemporary clinical data indicate replacement of the 99th percentile with the 97.5th percentile would lead to more patients being classified as having chronic myocardial injury, while the increase in NSTEMI would be minor (22). It has been argued, and we agree, that there is minimal evidence to support this change. Use of the 97.5th percentile would likely cause clinical confusion, encourage use of nonstandardized definitions for MI diagnosis, and reduce the validity of data collected from large epidemiology and therapeutic trials that have been used to derive treatment protocols for patients with MI. At present, laboratory

medicine, cardiology, and emergency medicine guidelines continue to support the 99th percentile (7).

## Selecting an Appropriate Reference Cohort to Derive the 99th Percentile

Currently, there are 2 hs-cTnT assays and multiple hs-cTnI assays that are globally commercially available (23). All have different performance characteristics depending on the instrumentation platform used to measure cTn, and each assay utilizes different capture and detection antibodies. Thus, assays are not standardized or harmonized. Accordingly, the 99th percentile URLs must be determined for each individual assay and platform.

**RECOMMENDATION 2: THE HS-CTN 99TH PERCENTILE URL SHOULD BE DERIVED FROM A REFERENCE COHORT OF HEALTHY INDIVIDUALS, APPROXIMATELY 50% MALE AND 50% FEMALE, WITH AN AGE RANGE FROM 18 AND UP TO 80 YEARS, AND ALL RELEVANT ETHNIC/RACIAL GROUPS SHOULD BE INCORPORATED**

Reference cohorts should exclude subjects with comorbidities or chronic conditions that potentially affect the heart,

nor should hospitalized patients be included in the applicable reference cohort for determining 99th percentiles. Including individuals with such comorbidities is not acceptable and will change the distribution of measured hs-cTn concentrations (1, 6), substantially influencing both the length and distortion of the upper tail, which significantly affects statistical calculations. Cohorts that exclude individuals who are prescribed medications related to cardiovascular disease or risk factors (e.g., aspirin, antihypertensive, antidiabetes drugs, or lipid-lowering drugs) have lower 99th percentiles compared to a less rigorously screened population; hence, these individuals should be excluded (8–10). Health status of the reference population should be initially screened using questionnaires (20) or a clinical visit, where participants are queried about comorbidities, chronic conditions, and medication use. Preinclusion screening criteria should also encompass surrogate biomarker testing to exclude undiagnosed subclinical disease, primarily diabetes, renal dysfunction, or myocardial dysfunction. We recommend a standardized and conservative approach toward exclusion of individuals treated for or diagnosed with any conditions that may influence and increase the hs-cTn 99th percentile URL (Table 1).

**Table 1. Conditions that should be excluded from the reference population.**

Condition	Screening tool
All known cardiovascular or cardiac diseases	Reported in questionnaire
Treatment for hyperlipidemia	Medication reported in questionnaire
Treatment for hypertension	Medication reported in questionnaire
Subclinical heart disease	Exclude if NT-proBNP >125 ng/L or BNP >35 ng/L (38)
Diabetes	Treatment (including diet) reported in questionnaire Exclude if HbA1c $\geq$ 48 mmol/mol ( $\geq$ 6.5%), fasting glucose $\geq$ 7.1 mmol/L (126 mg/dL), 2 hour plasma glucose during oral tolerance test (100 g) or a randomly measured glucose $\geq$ 11.1 mmol/L (200 mg/dL) (39)
Chronic renal disease	eGFR <60 mL/min/1.73 m <sup>2</sup> or urine albumin/creatinine ratio > 3 mg/mmol (>30 mg/g) (40)
Abnormal BMI	<18 m <sup>2</sup> /kg or >35 m <sup>2</sup> /kg
Smoking	Reported in questionnaire
Chronic disease that could affect the heart (cancer, lung, liver, unstable or nontreated thyroid disease, autoimmune diseases)	Reported in questionnaire
Recent acute hospitalization (within the last 3 months)	Reported in questionnaire
Pregnancy	Reported in questionnaire
For biotin sensitive assays only: Ongoing treatment with biotin (within one week)	Reported in questionnaire

NT-proBNP, N terminal pro brain natriuretic peptide; BNP, Brain natriuretic peptide; HbA1c, Hemoglobin A1c; eGFR, estimated glomerular filtration rate.

The relationship between age and cTn concentrations is complex, with some studies suggesting a direct relationship between age and cTn and others suggesting that with appropriate rigorous patient selection, this relationship disappears. For example, age has been shown to be a significant predictor of cTn concentrations, but this effect is substantially minimized if echocardiography screening is undertaken to eliminate cardiac pathology (9). Ideally, all age strata should be equally represented in the reference population, but recruitment of a large cohort of completely healthy >60-year-olds within a reasonable timeframe may be problematic; accordingly, age-stratified 99th percentile URLs are not recommended. A reasonable age distribution should still be attempted, with all age strata represented fairly within the reference cohort.

Differences in hs-cTn concentrations have been reported between ethnic groups; thus, the reference cohort should also include a representative distribution reflecting the regional ethnic composition in the applicable geographical area. Presently, some of the 99th percentile URLs for hs-cTn assays available in the United States are different compared to those utilized in the European Union and/or globally (depending on assay) (23), which may in part reflect these differences but also likely indicate variability in the enrollment criteria used since some manufacturers use convenience specimens rather than prospectively rigorously screened cohorts. It has not been determined whether region-specific hs-cTn 99th percentile URLs should be implemented in other parts of the world (e.g., Asia or Africa), but this needs to be explored further.

Myocardial imaging may further differentiate between myocardial healthy and diseased, and imaging criteria have been shown to further lower the 99th percentile estimate (9). Use of imaging procedures to screen participants comes with a substantial increase in cost and therefore is not required as part of the routine prescreening of individuals in the reference cohort. However, data from population-based cohort studies that used imaging could be part of a larger data set to determine the 99th percentile URL, and in such cases, normal cardiac findings may be documented.

**RECOMMENDATION 3: SEX-SPECIFIC HS-CTN 99TH PERCENTILE URLs SHOULD BE DETERMINED AND REPORTED**

Health and diagnostic disparities in women with cardiovascular disease are apparent, and outcomes are worse in females compared to males with cardiovascular disease (24). Sex-specific differences are also evident for hs-cTn assays, with lower 99th percentiles in females (23). This is believed to be largely due to differences in cardiovascular physiology (females have smaller cardiac mass by weight) as well as a higher incidence of

subclinical coronary artery disease in men at an earlier age (1). Due to varying analytical sensitivities of hs-cTn assays, 99th percentile differences may be subtle or significant, and assays that show measurable concentrations in larger percentages of a healthy cohort are seemingly more sensitive to detecting a difference between females and males. As for other analytes such as creatinine or creatine kinase, if sex-specific reference intervals are determined to be statistically significant, then clinical laboratories should report them. In this regard, hs-cTn should not be an outlier. Sex-specific URLs lead to greater recognition of disease and possible also cardiovascular risk, and the long-term prognostic power for hs-cTnI in particular is higher in women (25, 26). Whether attention or treatment to increased hs-cTn concentrations in females will impact outcomes is the focus of the ongoing randomized clinical trial hs-cTn Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI; NCT03819894).

**Statistical Recommendations Related to the 99th Percentile**

Statistical techniques and methods utilized for outlier exclusion greatly influence calculation of the 99th percentile. Appropriate statistical handling of data generated is as critical as selection of the reference population.

**RECOMMENDATION 4: THE 99TH PERCENTILE URL SHOULD BE DETERMINED USING THE NONPARAMETRIC METHOD OR A METHOD WITH SIMILAR STATISTICAL CAPABILITY, AND THE COHORT SHOULD PREFERABLY INCLUDE A MINIMUM OF 400 HEALTHY MALES AND 400 HEALTHY FEMALES, A TOTAL OF 800 SUBJECTS, TO DERIVE 99TH PERCENTILES WITH SUFFICIENT STATISTICAL POWER ALLOWING CALCULATION OF THE 95% CI**

We recommend using the nonparametric statistical method (or the Harrell-Davis method) as opposed to the robust method (27). The robust method was designed to establish a central 95% reference interval and not the 99th percentile and is therefore less accurate when the number of subjects is >120 and for biomarkers showing a skewed distribution. A minimum of 300 subjects per partition generates sufficient statistical uncertainties (CIs) of 90% at the 99th percentile (28). However, we are revising the recommendation to allow CIs of 95% to be utilized to minimize influence from outliers and increase reproducibility between cohorts, which will in turn increase the minimum number of subjects to 400 males and 400 females (minimum of 800 total subjects) (28). According to this method, the appropriate cutoff concentration corresponding to the hs-cTn 99th percentile URL is determined by the 4 highest observations. If  $n = 400$ , then the low and

high 95% CIs will be determined by persons ranged as number 391 and 400, respectively, and the 99th percentile will be similar to the concentration between observation number 395 and 396 of the reference cohort. A rigid clinical selection of participants in the healthy cohort should minimize the risk of outliers due to unrecognized cardiac disease, and outlier exclusion should therefore be conservative. The Reed/Dixon criteria may be preferred as it will exclude fewer subjects than the Tukey method (27). Bootstrapping methods may be useful for calculation of CIs as this will increase certainty of the estimated limits. CIs should not be reported clinically but should be disclosed in clinical research trials and studies reported in peer-reviewed journals.

**RECOMMENDATION 5: BIOLOGICAL INTERFERENCES SHOULD BE INVESTIGATED IN SPECIMENS WITH HS-CTN RESULTS THAT ARE OUTLIERS WITHOUT A VALID CLINICAL EXPLANATION**

Even though a strict clinical screening will be undertaken, biological confounders should be taken into consideration when deriving the 99th percentile URLs for hs-cTn assays. Like all immunoassays, cTn-assays may infrequently be affected by antibodies that bind cTn or components of the assay. These complexation effects can sometimes result in stable increased cTn concentrations up to 10× the URL, and have been designated “macro-troponin.” The presence of macro-troponin can be determined by reasonable, easy methods involving removal of the immunoglobulins in the sample (29) and should be considered a concern when apparently healthy individuals show unexpectedly high concentrations. Interferences from heterophile antibodies (endogenous antibodies that may interfere with different clinical immunoassays) can also be present, whereby the heterophile antibodies cross-react with the cTn antibodies and provide a false-positive or negative result. Circulating anti-cTn antibodies can also result in false low cTn concentrations in rare cases, but since the 99th URL is determined using the highest cTn values, the concerns are focused primarily around macro-troponin. We recognize the challenge of assay design to minimize both macro-troponin, heterophile, and/or autoantibody interferences. Clinically, patients with these interferences routinely undergo extensive and unnecessary clinical investigation, with additional investigation using a different hs-cTn assay and/or imaging tests revealing normal results. If healthy subjects with macro-troponin, heterophile, or autoantibody antibodies incidentally are enrolled in the reference population, this could artificially shift the 99th percentile to a higher hs-cTn concentration (29). Accordingly, these individuals should be excluded based on outlier testing or

clinical suspicion if diagnosed by relevant analytical techniques (29).

**Laboratory Variables That May Affect the 99th Percentile**


In addition to identification of biological confounders, stringent preanalytical and analytical criteria are critical to accurately calculate the 99th percentile URL.

**RECOMMENDATION 6: PREANALYTICAL PROTOCOLS AND ANALYTICAL INTERFERENCES SHOULD BE STANDARDIZED AND OPTIMIZED FOR ACCURATE DETERMINATION OF 99TH PERCENTILE URLS**

There are numerous important preanalytical factors that may influence accurate determination of hs-cTn results, including body position, time of day, centrifugation speed, storage time before analyzing, interfering substances, and collection tubes. hs-cTnT demonstrates diurnal variation (30, 31); thus, timing for specimen collection should be standardized. Hemolysis may cause false-negative (hs-cTnT) or false-positive (hs-cTnI, assay dependent) results (32–34), and specimens may be compromised due to icterus or turbidity/lipemia (hs-cTnI) (32). Hemolysis, icterus, and lipemia should be verified in all specimens obtained when determining 99th percentiles and excluded based on the applicable assay-specific cutoffs for interferences > 10%. Individuals who consume biotin daily may have false-negative results with some hs-cTn assays that are dependent on biotin/streptavidin binding properties (34). Different additives used in plasma collection tubes (e.g., heparin or EDTA) may also affect hs-cTn concentrations (23, 35). Specimen type, collection tubes, and additives should be evaluated, and if significant differences exist, then different hs-cTn 99th URLs should be derived for each tube/additive as applicable.

**RECOMMENDATION 7: UNAVOIDABLE LOT-TO-LOT ANALYTICAL UNCERTAINTY SHOULD BE INTEGRATED IN DETERMINATION OF THE 99TH PERCENTILE URL**

Studies have reported instrument dependent lot-to-lot variability in hs-cTn reagents and/or calibrators, shifting concentrations  $\pm 1$ –2 ng/L over time, with lower concentrations near the limit of detection being affected the greatest (36, 37). Therefore, if all specimens from the reference population are measured using the same reagent and/or calibrator lot, the hs-cTn concentration defined as the 99th percentile may deviate upward or downward in accordance with the concentration value of that particular lot. It is uncommon for clinical laboratories to use multiple reagent or calibrator lots simultaneously. Thus, to mitigate this risk, specimens from the reference population could be analyzed across different



laboratories or over a longer period of time. Several modules of the same instrument should be used within the applicable laboratory to ensure that reagent and calibrator lot-to-lot variability, as well as intra- and interlaboratory differences and uncertainties, are incorporated into the data set to increase the overall robustness of the statistical calculations. This could be done by either (a) performing a multicenter study, (b) merging data from healthy individuals included in population-based cohort studies, or (c) using biobanked specimens that are analyzed across multiple laboratories, with the included sites/cohorts/laboratories utilizing different reagent and calibrator lots (Fig. 2).

### Future Needs

Increasing clinical knowledge related to the diagnostic and prognostic performance of hs-cTn assays allow for improvement in patient triage and clinical care strategies. Future developments for increasing the analytical sensitivity and imprecision of cTn assays are likely to further improve categorization of patients in the ED. Improved technology in artificial intelligence systems and machine learning algorithms could potentially integrate information regarding age, sex, ethnicity, comorbidity, and hs-cTn results that are available in electronic medical records, making it possible to automatically identify presence of acute or chronic myocardial injury or risk scores both for short- and long-term major adverse cardiovascular events. This ultimately could be reported clinically in electronic health records

to improve prognosis and outcomes. High-quality studies based on reliable hs-cTn data measurements are key for future research studies.

### Conclusion

The hs-cTn 99th percentile URL is a key threshold in the UDMI and throughout routine clinical and laboratory practice. To increase harmonization of acute MI diagnosis, the 99th percentile URL should be determined in a standardized/harmonized manner, including rigorous clinical and analytical screening procedures; sufficient number of included participants; acknowledging of all preanalytical, analytical, and biological factors affecting the cTn assay; and adequate statistical handling, that may affect the estimates.

**Nonstandard Abbreviations:** cTn, cardiac troponin; hs-cTn: high-sensitivity cardiac troponin; UDMI, Universal Definition of Myocardial Infarction; MI, myocardial infarction; ED, emergency department; URL, upper reference limit; NSTEMI, non-ST-elevation myocardial infarction.

**Author Contributions:** All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

**Authors' Disclosures or Potential Conflicts of Interest:** Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest.

**Employment or Leadership:** F.S. Apple, *Clinical Chemistry*, AACC. P. Collinson, *The Journal of Applied Laboratory Medicine*, AACC, and a fiduciary role with Radiometer. T. Omland has a fiduciary role in CardiNor. R. Body has a fiduciary role in Royal College of Emergency Medicine Research Committee.

**Consultant or Advisory Role:** K.M. Aakre has served on advisory boards for Roche Diagnostics and received consulting fees from CardiNor. A.K. Saenger has received consulting fees from Radiometer. R. Body has received consulting fees from Roche, Aptamer Group, Abbott, Sysco, Siemens Healthineers, Beckman Coulter, and Radiometer and participated in advisory boards for FORCE Trial (NIHR funded), REWIRE trial (Queen Mary University, London), PRONTO trial (NIHR funded), LumiraDx (advisory board). A.S. Jaffe has received consultant fees from Abbott, Siemens, Radiometer, Ortho Diagnostics, Beckman Coulter, Sphingotec, Roche, ET Healthcare, Amgen, and Novartis. P. Kavsak has received consulting fees from Abbott Point of Care, Roche, Siemens, Beckman Coulter, and Quidel. P. Collinson has participated in advisory board for Sysco Diagnostics. T. Omland has received consultant fees from Roche, Bayer, and CardiNor and participated in advisory board for Bayer and Roche. F.S. Apple has served as a consultant for HyTest Ltd and on advisory boards for Werfen, Siemens Healthineers, and Qorvo.

**Stock Ownership:** A.S. Jaffe has stock options with RCE Technologies. O. Hammarsten has stock options with <https://www.alignedbio.com/>. T. Omland has stocks in CardiNor.

**Honoraria:** K.M. Aakre has received lecturing fees from Roche Diagnostics, Siemens Healthineers, and SNIBE Diagnostics. R. Body has received lecturing fees from EMCREG (Emergency Medicine Cardiac Research & Education Group) International. P. Kavsak has received honoraria from Beckman Coulter, Siemens, Roche, and Thermo Fisher Scientific. T. Omland has received honoraria from Roche. F.S. Apple received honorarium for speaking at industry conferences for Siemens Healthineers and Beckman Coulter.

**Research Funding:** K.M. Aakre has received research material support from Siemens Healthineers and Roche Diagnostics. R. Body has received grants from Siemens Healthineers, Abbott Point of Care, National Institute of Health Research, Asthma UK, British Lung Foundation, UK Department of Health, and Social Care and service from My110, Randox, Avacta, LumiraDx, Chronomics, iXensor, BD, and Horiba. P. Kavsak has received grants from Abbott, Beckman, Ortho, Randox, Roche, and Siemens. T. Omland has received equipment/material from Novartis and Abbott. F.S. Apple is the principal investigator on industry-funded grants (nonsalaried) on

cardiac biomarkers through Hennepin Healthcare Research Institute: Abbott Diagnostics, Abbott POC, BD, Beckman Coulter, Ortho-Clinical Diagnostics, Roche Diagnostics, and Siemens Healthcare.

**Expert Testimony:** None declared.

**Patents:** McMaster University has filed patents with P. Kavsak listed as an inventor on quality control materials for cardiac troponin testing and identifying pregnant women at increased risk for hypertension and future cardiovascular disease. McMaster University has filed a patent with P. Kavsak listed as an inventor in the acute cardiovascular biomarker field; in particular, a patent has been awarded in Europe (EP 3 341 723 B1) on a method of determining risk of an adverse cardiac event. T. Omland has one patent application: GDF-15 for Predicting the Disease Severity of a Patient With COVID-19.

**Other Remuneration:** P. Kavsak has received travel support from Randox Laboratories.

**Role of Sponsor:** The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of manuscript.

## References

1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). *Circulation* 2018;138:e618–51.
2. Collet JP, Thiele H, Barbato E, Barthelémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2021;42:1289–367.
3. Neumann JT, Twerenbold R, Ojeda F, Sorensen NA, Chapman AR, Shah ASV, et al. Application of high-sensitivity troponin in suspected myocardial infarction. *N Engl J Med* 2019;380:2529–40.
4. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. *Circulation* 2021;144:e368–454.
5. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes. *Circulation* 2007;115:e352–5.
6. Wu AHB, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordóñez-Llanos J, Apple FS. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem* 2018;64:645–55.
7. Sandoval Y, Apple FS, Saenger AK, Collinson PO, Wu AHB, Jaffe AS. 99th percentile upper-reference limit of cardiac troponin and the diagnosis of acute myocardial infarction. *Clin Chem* 2020;66:1167–80.
8. Collinson PO, Heung YM, Gaze D, Boa F, Senior R, Christenson R, Apple FS. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. *Clin Chem* 2012;58:219–25.
9. McKie PM, Heublein DM, Scott CG, Gantzer ML, Mehta RA, Rodeheffer RJ, et al. Defining high-sensitivity cardiac troponin concentrations in the community. *Clin Chem* 2013;59:1099–107.
10. Koerbin G, Abhayaratna WP, Potter JM, Apple FS, Jaffe AS, Ravalico TH, Hickman PE. Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. *Clin Biochem* 2013;46:1636–43.
11. Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin t. *Ann Emerg Med* 2016;68:76–87.e4.
12. Twerenbold R, Neumann JT, Sorensen NA, Ojeda F, Karakas M, Boeddinghaus J, et al. Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction. *J Am Coll Cardiol* 2018;72:620–32.
13. Wereski R, Kimenai DM, Taggart C, Doudesis D, Lee KK, Lowry MTH, et al. Cardiac troponin thresholds and kinetics to differentiate myocardial injury and myocardial infarction. *Circulation* 2021;144:528–38.
14. Chiang CH, Chiang CH, Pickering JW, Stoyanov KM, Chew DP, Neumann JT, et al. Performance of the European society of cardiology 0/1-hour, 0/2-hour, and 0/3-hour algorithms for rapid triage of acute myocardial infarction: an international collaborative meta-analysis. *Ann Intern Med* 2022;175:101–13.
15. Lyngbakken MN, Aagaard EN, Kvisvik B, Berge T, Pervez MO, Brynildsen J, et al. Cardiac troponin I and T are associated with left ventricular function and structure: data from the Akershus Cardiac Examination 1950 study. *Clin Chem* 2020;66:567–78.
16. Hammarsten O, Mair J, Mockel M, Lindahl B, Jaffe AS. Possible mechanisms behind cardiac troponin elevations. *Biomarkers* 2018;23:725–34.
17. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. *Nat Rev Cardiol* 2015;12:547–58.
18. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. *N Engl J Med* 2009;361:2538–47.
19. Sandoval Y, Smith SW, Sexter A, Gunsolus IL, Schulz K, Apple FS. Clinical features and outcomes of emergency department patients with high-sensitivity cardiac troponin I concentrations within sex-specific reference intervals. *Circulation* 2019;139:1753–5.
20. Clinical and Laboratory Standards Institute. C28-a3c. Defining, establishing and verifying reference intervals in the clinical laboratory; approved guideline, third edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2008.
21. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, Katus H. It's time for a



- change to a troponin standard. *Circulation* 2000;102:1216–20.
22. Eggers KM, Aldous S, Greenslade JH, Johnston N, Lindahl B, Parsonage WA, et al. Two-hour diagnostic algorithms for early assessment of patients with acute chest pain—implications of lowering the cardiac troponin I cut-off to the 97.5th percentile. *Clin Chim Acta* 2015;445:19–24.
  23. Apple F, Kavsak P, Hammarsten O, Saenger A, Body R, Lam SPC, et al. Committee on Clinical applications of Cardiac Bio-Markers (C-CB). <https://www.lfcc.org/media/478231/high-sensitivity-cardiac-troponin-i-and-t-assay-analytical-characteristics-designated-by-manufacturer-v122019.pdf> (Accessed August 2021).
  24. Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. *Circulation* 2016;133:916–47.
  25. Lee KK, Ferry AV, Anand A, Strachan FE, Chapman AR, Kimenai DM, et al. Sex-specific thresholds of high-sensitivity troponin in patients with suspected acute coronary syndrome. *J Am Coll Cardiol* 2019;74:2032–43.
  26. Lyngbakken MN, Rosjo H, Holmen OL, Nygard S, Dalen H, Hveem K, Omland T. Gender, high-sensitivity troponin i, and the risk of cardiovascular events (from the Nord-Trøndelag Health Study). *Am J Cardiol* 2016;118:816–21.
  27. Eggers KM, Apple FS, Lind L, Lindahl B. The applied statistical approach highly influences the 99th percentile of cardiac troponin I. *Clin Biochem* 2016;49:1109–12.
  28. Meeker WQ, Hahn GJ, Escobar LA. Statistical intervals: a guide for practitioners and researchers. 2nd ed. Hoboken (NJ): John Wiley & Sons, Inc.; 2017.
  29. Lam L, Aspin L, Heron RC, Ha L, Kyle C. Discrepancy between cardiac troponin assays due to endogenous antibodies. *Clin Chem* 2020;66:445–54.
  30. Klinkenberg LJ, van Dijk JW, Tan FE, van Loon LJ, van Dieijen-Visser MP, Meex SJ. Circulating cardiac troponin T exhibits a diurnal rhythm. *J Am Coll Cardiol* 2014;63:1788–95.
  31. Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin t and cardiac troponin I in hemodialysis patients and healthy controls. *Clin Chem* 2014;60:838–47.
  32. Kwon HJ, Seo EJ, Min KO. The influence of hemolysis, turbidity and icterus on the measurements of CK-Mb, troponin I and myoglobin. *Clin Chem Lab Med* 2003;41:360–4.
  33. Wei J, Wu YN, Ling Y, Chen XT, Zhu Q, Xu J. False decrease of high-sensitivity cardiac troponin T assay in pneumatic tube system samples. *Clin Chim Acta* 2019;495:507–11.
  34. Harley K, Bissonnette S, Inzitari R, Schulz K, Apple FS, Kavsak PA, Gunsolus IL. Independent and combined effects of biotin and hemolysis on high-sensitivity cardiac troponin assays. *Clin Chem Lab Med* 2021;59:1431–43.
  35. Kavsak PA, Malinowski P, Roy C, Clark L, Lamers S. Assessing matrix, interferences and comparability between the Abbott Diagnostics and the Beckman Coulter high-sensitivity cardiac troponin I assays. *Clin Chem Lab Med* 2018;56:1176–81.
  36. Lyon AW, Kavsak PA, Lyon OA, Worster A, Lyon ME. Simulation models of misclassification error for single thresholds of high-sensitivity cardiac troponin I due to assay bias and imprecision. *Clin Chem* 2017;63:585–92.
  37. Haagensen K, Collinson P, Asberg A, Aakre KM. How does the analytical quality of the high-sensitivity cardiac troponin T assay affect the esc rule out algorithm for NSTEMI? *Clin Chem* 2019;65:494–6.
  38. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail* 2021;23:352–80.
  39. World health organization. Classification of diabetes mellitus. <https://www.who.int/publications/i/item/classification-of-diabetes-mellitus> (Accessed June 2022).
  40. Andrassy KM. Comments on “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.” *Kidney Int* 2013;84:622–3.